Search
Avutometinib
go.drugbank.com/drugs/DB15254ApprovedInvestigational[L53203,L53198] The MAPK pathway is implicated in variety of cancers, playing a key role in tumor cell proliferation, differentiation and survival. … [L53203] It has been under investigation in humans since at least 2012.
Synonyms: N-(3-fluoro-4-((4-methyl-2-oxo-7-((pyrimidin-2-yl)oxy)-2H-1-benzopyran-3-yl)methyl)pyridin-2-yl)-N'-methylsulfuric diamide, Sulfamide, N-(3-fluoro-4-((4-methyl-2-oxo-7-(2-pyrimidinyloxy)-2H-1-benzopyran-3-yl)methyl)-2-pyridinyl)-N'-methyl-WP-1122
go.drugbank.com/drugs/DB17192InvestigationalWP-1122 is a prodrug of 2-deoxy-D-glucose (2-DG). It was granted FDA orphan designation for the treatment of glioblastoma multiforme.[L47361]
Synonyms: an acetic acid diester of 2-deoxy-D-glucoseUrelumab
go.drugbank.com/drugs/DB12077InvestigationalThe antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with … Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma.
Rurioctocog alfa pegol
go.drugbank.com/drugs/DB16007ApprovedInvestigationalIt was first approved by the European Commission in January 2018. … Factor VIII is an essential protein involved in normal blood clotting; thus, a deficient level of functional factor VIII is associated with an elevated risk for excessive bleeding caused by spontaneous
Synonyms: Antihemophilic factor (recombinant), pegylated (20 kda), Antihemophilic factor (recombinant), pegylated (mw 20000)Estetrol
go.drugbank.com/drugs/DB12235ApprovedInvestigationalEstetrol is the first new estrogen introduced to the USA in over 50 years and is the first approved estetrol product in the world. … [L33179] In Canada, Nextstellis was approved for use in March 2021; it was developed by Mithra and is marketed by Searchlight Pharma.[L33209]
Bendazac
go.drugbank.com/drugs/DB13501ApprovedWithdrawnBendazac, however, has since been withdrawn or discontinued in various international regions due to its capability or risk for eliciting hepatotoxicity [A39891, A39892, A39893, L4778] in patients although … the denaturation of proteins - an effect that has primarily proven useful in managing and delaying the progression of ocular cataracts [A39863.
Apadamtase alfa
go.drugbank.com/drugs/DB15164ApprovedInvestigational[A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP. … metalloproteinase with a thrombospondin type 1 motif, member 13), which is responsible for cleaving large von Willebrand factor multimers and preventing the formation of microthrombi - this deficiency in
Telotristat ethyl
go.drugbank.com/drugs/DB12095Approved[A252937] Serotonin is metabolized in the urinary metabolite 5-hydroxy indole acetic acid (u5-HIAA), and high levels of u5-HIAA is associated with poor survival outcome in patients with NET. … Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo.
Ganulameran
go.drugbank.com/drugs/DB16442InvestigationalAs such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949). … Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it.
MT-0169
go.drugbank.com/drugs/DB17430InvestigationalMT-0169 is a usion protein comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to a human single chain variable fragment with affinity for human CD38 cell surface protein.